determine whether myofilaments activated with ADP (without Ca) are sensitive to kinase treatment. Results: We show that ADP, in the absence of Ca, accelerates cross-bridge cycling and force development in cardiomyocytes from HF patients, which was sensitive to PKA-mediated phosphorylation (i.e. decreased sensitivity to ADP). Casensitivity increased in the presence of increasing [ADP] and was accompanied by significant slowing cross-bridge cycling kinetics. This was correlated with significant increases in residual force enhancement (i.e. high initial tension recovery). Conclusions: The current data show that high [ADP] reduces the ability to desensitize myofilaments to Ca, which likely compromises restoration of end-diastolic length. High ADP increased cross-bridge strain (i.e. diastolic dysfunction) and depressed myofilament cycling kinetics, which may limit muscle shortening (i.e. systolic dysfunction). The present study suggests that inability to lower myocardial ADP levels can be a primary determinant of contractile dysfunction and disease progression in human HF.
1002-Plat Myocardial Strain Rate Modulates the Speed of Relaxation in Dynamically
Loaded Twitch Contractions Kenneth S. Campbell, Charles S. Chung. Physiology and Center for Muscle Biology, University of Kentucky, Lexington, KY, USA. Slow myocardial relaxation is an important clinical problem in about 50% of patients who have heart failure. Prior experiments had suggested that the slow relaxation might be a consequence of high afterload (hypertension) but large clinical trials testing this hypothesis have failed; lowering blood pressure in patients who have heart failure with preserved ejection fraction does not help clinical outcomes. We performed new experiments using mouse, rat, and human trabeculae (Chung et al., Biophys J. 106,564a, 2014) and showed that it is not afterload but the strain rate at end systole that determines the subsequent speed of relaxation. To investigate the molecular mechanisms that drive this behavior, we ran simulations of our mechanical experiments using the freely available software MyoSim (http://www.myosim.org). This software simulates the mechanical properties of dynamically activated half-sarcomeres by extending A.F.Huxley's cross-bridge distribution technique with calcium activation and cooperative effects. We discovered that our experimental data could be reproduced using a relatively simple framework consisting of a single halfsarcomere pulling against a series elastic spring. Further analysis of the simulations suggested that quick stretches speed myocardial relaxation by detaching myosin heads and thereby disrupting the cooperative mechanisms that would otherwise prolong thin filament activation. The simulations therefore identify myofilament kinetics and tissue strain rate as potential therapeutic targets for heart failure attributed to slow relaxation. -regulated by thin-filament proteins and sarcomere length, which dictates the number of potential actin-myosin cross-bridge interactions. One mechanism underlying greater cardiac contractility at longer SL could involve longer myosin attachment duration (t on ). To test this idea, we used stochastic length-perturbation analysis in skinned rat papillary muscle strips to measure t on as [MgATP] varied (0.05-5 mM) at 1.9 and 2.2 mm SL. From this t on -MgATP relationship, we calculated cross-bridge MgADP release rate (k -ADP ) and MgATP binding rate (k þATP ). As MgATP increased t on decreased hyperbolically for both SL, but t on was roughly 50% longer for 2.2 vs. 1.9 mm SL at each [MgATP] The cardiac cycle is a tightly regulated process in which the heart generates power during systole and relaxes during diastole. Appropriate power must be generated to effectively pump blood against cardiac afterload. Dysfunction of this cycle has devastating consequences for affected individuals. Cardiac power output is regulated by several feedback mechanisms (e.g. neuronal, hormonal, mechanical) which ultimately lead to changes in the force and power output of the molecular motor, b-cardiac myosin (bCM). Despite its importance in driving and regulating cardiac power output, the effect of force on the contractility of a single bCM has not been measured at physiological [ATP] . Using optical trapping techniques, we found that similar to some other myosins, bCM has a two-substep working stroke where the second mechanical substep is associated with ADP release. At saturating [ATP] (4 mM), forces that resist the power stroke slow myosin-driven contraction, suggesting that the inherent properties of myosin contribute to the force-velocity relationship in muscle and play an important role in the regulation of cardiac power output. Based on our results and kinetic modeling, we propose that force inhibits the mechanical transition associated with ADP release, leading to slowing of the rate of ADP release, the same kinetic step that limits muscle shortening. These results have important implications for cardiac diseases which affect power output, such as heart failure and cardiomyopathies. This work was supported by the American Heart Association (14SDG18850009 to M.J.G.) and National Institutes of Health (R01GM057247 to E.M.O. and K99HL123623 to M.J.G.). College of Science, Northeastern University, Boston, MA, USA. A significant number of cardiac myopathies in children and adults are caused by mutations in the cMyBP-C gene. In disease, cardiac output is compromised by altered cardiac muscle fiber contractility due to modulated interactions between cMyBP with actin or with S2. Comparative measurements in WT and knockout mice (cMyBP-C -/-) muscle fibers have showed increased isotonic shortening velocity, power output and rate of force redevelopment in absence cMyBP-C. Thus, change of only a few amino acids in mutant cMyBP-C, especially in regions rich with phosphorylation sites, may cause significant change in dynamics of muscle contractility. Comparison of measured sliding velocities of actin filaments over the regions of myosin filament with and without cMyBP-C in motility assays have provided molecular insight how these structural changes alter the kinetics of the interactions of cMyBP-C with myosin and actin filaments. We used a multi-scale, computational modelling platform, MUSICO, (MUscle SImulation COde) to assess the effect of cMyBP-C mutations on sarcomere contraction. This platform includes explicit 3-D sarcomere structures, extensible actin and myosin filaments, various models for the actomyosin cycles, thin filament regulation via a continuous flexible chain (CFC) model and now cMyBP-C using the kinetic parameters for dynamically forming and disrupting connections between cMyBP-C and actin, derived from the motility studies. We compared the model predictions between different mutations and the corresponding mechanical experiments. The predictions from cMyBP-C sarcomeric model showed significant differences between the mutants, and closely followed observations. This results allow the quantitative evaluation of the role of cMyBP-C in the regulation of sarcomere structure and function, the development of a multi-scale myoarchitectural representation of disease phenotype and the creation of a novel diagnostic and prognostic methodology for tracking disease progression in patients. Supported by: R01s AR048776 and DC 011528
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